PKM and Alzheimer disease: The increase of CSF PKM activity in both AD and FTD patients might be assumed as a proxy biomarker either for altered glucose metabolism occurring in the brain of these subjects [52] or for a general neurodegeneration process, where PKM is released in CSF due to cell death.